COMMUNIQUÉS West-GlobeNewswire

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
14/11/2017
- All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland and Boston, MA - November 14, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical [...]
AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
14/11/2017
ALACHUA, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej [...]
VBL Therapeutics Announces Third Quarter 2017 Financial Results
14/11/2017
Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development [...]
Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
14/11/2017
HAIFA, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, today reported financial results and corporate [...]
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195
14/11/2017
– Up to $1.55B in Upfront, Regulatory, and Commercial Milestones – – Loxo Oncology and Bayer to Co-Promote in U.S. with a 50/50 Profit Share; Bayer to Commercialize ROW – – Loxo Oncology to Lead Global Development [...]
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
14/11/2017
-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two Pivotal Trials of DCC-2618 [...]
UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments
14/11/2017
RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN ), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with [...]
Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer
14/11/2017
Distributor Accutest Now Selling Through Today’s Group THOROFARE, N.J, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health [...]
Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology
14/11/2017
CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. ( www.neuronascent.com ), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today announced the European [...]
Transactions in relation to share buyback program
14/11/2017
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
DiamiR Announces Publication of Data on microRNA Biomarkers for Neurodegenerative Diseases in Alzheimer’s Research & Therapy
14/11/2017
MONMOUTH JUNCTION, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today the publication of "Circulating [...]
BioNovelus agrees to Co-Directorship and advisory with Meroe Capital Group Ltd.
14/11/2017
FOR IMMEDIATE RELEASE — Phoenix, Nov. 14, 2017 (GLOBE NEWSWIRE) -- — BioNovelus (ONOV) has today announced the retention of New York-based Meroe Capital Group Ltd. In the structure of the deal, BioNovelus will become a [...]
Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide
14/11/2017
Press Release- No. 11/2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide All 75 subjects dosed with glepaglutide in the clinical trial The [...]
Early close of offering of shares in Orphazyme
14/11/2017
Company announcement Orphazyme A/S No. 3/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 14 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN [...]
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14/11/2017
Presentation of results from the Kisqali ® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses focused on quality of life, [...]
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
14/11/2017
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety [...]
Targovax to present at upcoming investor conferences
14/11/2017
Oslo, Norway, 14 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present at [...]
Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound Weighing an Appeal
14/11/2017
YAVNE, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD ), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound [...]
MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications
14/11/2017
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis System. MolecularMD [...]

Pages